Trial Profile
A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation - Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Antithymocyte globulin; Basiliximab; Ciclosporin; Corticosteroids; Methylprednisolone; Mycophenolate mofetil; Mycophenolate sodium; Prednisone; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms TRANSFORM
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 01 Sep 2021 Results assessing effect of tacrolimus exposure on everolimus based immunosuppression in De Novo Kidney Transplant Recipients a 24- Month, presented at the 20th Congress of the European Society for Organ Transplantation
- 01 Sep 2021 Results assessing Infection Pattern in various subgroups ,Everolimus Versus Mycophenolate-Based Regimens in Kidney Transplant Recipients presented at the 20th Congress of the European Society for Organ Transplantation
- 03 Jul 2021 Results of sub-group analysis in Asian de novo kidney transplant recipients, published in the Clinical Transplantation.